Almond for mild to moderate Alzheimer's disease: A randomized clinical trial.

Read full text
Authors: Mohsen Mohajeri, Fataneh Hashem-Dabaghian, Shima Raeesi, Somaye Mehroozade
Cited by: 1

Abstract

Objective: ) on memory and cognitive functions in patients with Alzheimer's disease (AD). Materials and Methods: In this randomized controlled trial, 60 AD patients with mild to moderate cognitive disorder were randomly allocated into an almond group (10 g/day powdered sweet almond plus 1 teaspoon of powdered rock candy along with their previous prescriptions), or the control group (continue previous prescriptions) for 3 months. The Mini-mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA), Clinical Dementia Rating (CDR), and Functional Assessment Staging (FAST) questionnaires were completed at the beginning and the end of the study. The sleep quality was also assessed by the Pittsburg Sleep Quality Index (PSQI). Results: Thirty participants in each group completed the study, and were analyzed. Age was 71.86±8.04 years in the almond group and 71.3±7.18 years in the control group (p=0.775). Duration of memory deficit was 2.8±0.92 and 3±1.2 months in the almond and control group, respectively (p=0.473). The orientation scale of the MMSE (p=0.024), MOCA (p=0.001), memory scale of MOCA (p=0.005), FAST (p=0.032), and PSQI (p

Fields of Study & Subjects

Nuts composition and effects Genetic Neurodegenerative Diseases Bee Products Chemical Analysis

Publication details

Journal / source
PubMed
Volume
16
Issue
2
Pages
1–12
Publication date
21 April 2026
Language
EN